EMAIL THIS PAGE TO A FRIEND

Viruses

Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism.


PMID 26516900

Abstract

Tetherin is an interferon-induced, intrinsic cellular response factor that blocks release of numerous viruses, including Ebola virus, from infected cells. As with many viruses targeted by host factors, Ebola virus employs a tetherin antagonist, the viral glycoprotein (EboGP), to counteract restriction and promote virus release. Unlike other tetherin antagonists such as HIV-1 Vpu or KSHV K5, the features within EboGP needed to overcome tetherin are not well characterized. Here, we describe sequences within the EboGP ectodomain and membrane spanning domain (msd) as necessary to relieve tetherin restriction of viral particle budding. Fusing the EboGP msd to a normally secreted form of the glycoprotein effectively promotes Ebola virus particle release. Cellular protein or lipid anchors could not substitute for the EboGP msd. The requirement for the EboGP msd was not specific for filovirus budding, as similar results were seen with HIV particles. Furthermore trafficking of chimeric proteins to budding sites did not correlate with an ability to counter tetherin. Additionally, we find that a glycoprotein construct, which mimics the cathepsin-activated species by proteolytic removal of the EboGP glycan cap and mucin domains, is unable to counteract tetherin. Combining these results suggests an important role for the EboGP glycan cap and msd in tetherin antagonism.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2501632
Anti-BST2 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1400028
Anti-BST2 antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
PRS4661
Anti-BST2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA017060
Anti-BST2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1400029
Anti-BST2 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB4500221
Anti-BST2 antibody produced in rabbit, affinity isolated antibody
F7425
ANTI-FLAG® antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
V8137
Anti-V5 antibody produced in rabbit, IgG fraction of antiserum
G3126
L-Glutamine, ReagentPlus®, ≥99% (HPLC)
C5H10N2O3
G5792
L-Glutamine, PharmaGrade, Ajinomoto, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
C5H10N2O3
G8540
L-Glutamine, meets USP testing specifications, cell culture tested, 99.0-101.0%, from non-animal source
C5H10N2O3
G6392
L-Glutamine, γ-irradiated, BioXtra, suitable for cell culture
C5H10N2O3
49419
L-Glutamine, BioUltra, ≥99.5% (NT)
C5H10N2O3
W368401
L-Glutamine
C5H10N2O3
SAB1403618
Monoclonal Anti-BST2 antibody produced in mouse, clone 2E6, purified immunoglobulin, buffered aqueous solution
SAB1402131
Monoclonal Anti-BST2, (C-terminal) antibody produced in mouse, clone 3H4, purified immunoglobulin, buffered aqueous solution
V8012
Monoclonal Anti-V5 antibody produced in mouse, ~1 mg/mL, purified immunoglobulin, clone V5-10